Allison R. Schulman

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Obesity is a complex, multifactorial chronic disease. With the development of novel endoscopic techniques and devices for the treatment of obesity, combined with expanding indications for medications, gastroenterologists are more involved in weight management than ever before. Despite the modern definition of obesity as a disease, weight bias and stigma are pervasive in the medical community and beyond. These sentiments contribute to worse outcomes for patients. Furthermore, body mass index (BMI), which is the primary metric to define obesity, does not always approximate visceral adiposity in all populations. A weight-centric model of health, which relies on BMI, misclassifies individuals who may be metabolically healthy at elevated weights. This review will summarize the history of BMI, highlight the problems that arise with a weight-centric model of health, and propose alternative weight-inclusive frameworks for assessment and intervention.

Year:

2024

Endoscopic sleeve gastroplasty (ESG) is an incisionless gastric remodeling procedure for the management of obesity which leads to a reduction in the size of the gastric lumen, prolongs gastric emptying, and changes in hormonal mechanisms that alter satiation. While a variety of suture patterns have been explored and technique may vary between endoscopists, the basic steps of ESG include (1) diagnostic esophagogastroduodenoscopy, (2) consideration of mucosal marking to guide suture placement, (3) placement of running sutures from distal to proximal along the greater curvature with intermittent reinforcement stitches. While this manuscript will predominantly focus on the technical aspects of performing the ESG procedure, knowledge of the cognitive components of bariatric endoscopy are critical to the success of this procedure in clinical practice.

Year:

2024

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach. Experimental Design: We performed subtyping on a single-cell RNA sequencing dataset containing 18 human PDAC samples to identify multiple intermediary subtypes. We generated patient-derived PDAC organoids for functional studies. We compared single-cell profiling of matched blood and tumor samples to measure changes in the local and systemic immune microenvironment. We then leveraged longitudinally patient-matched blood to follow individual patients over the course of chemotherapy. Results: We identified a cluster of KRT17 -high intermediary cancer cells that uniquely express high levels of CXCL8 and other cytokines. The proportion of KRT17 high /CXCL8 + cells in patient tumors correlated with intratumoral myeloid abundance, and, interestingly, high protumor peripheral blood granulocytes, implicating local and systemic roles. Patient-derived organoids maintained KRT17 high /CXCL8 + cells and induced myeloid cell migration in a CXCL8-dependent manner. In our longitudinal studies, plasma CXCL8 decreased following chemotherapy in responsive patients, while CXCL8 persistence portended worse prognosis. Conclusions: Through single-cell analysis of PDAC samples, we identified KRT17 high /CXCL8 + cancer cells as an intermediary subtype, marked by a unique cytokine profile and capable of influencing myeloid cells in the tumor microenvironment and systemically. The abundance of this cell population should be considered for patient stratification in precision immunotherapy. See related commentary by Faraoni and McAllister, p. 2297

Year:

2024

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach. Experimental Design: We performed subtyping on a single-cell RNA sequencing dataset containing 18 human PDAC samples to identify multiple intermediary subtypes. We generated patient-derived PDAC organoids for functional studies. We compared single-cell profiling of matched blood and tumor samples to measure changes in the local and systemic immune microenvironment. We then leveraged longitudinally patient-matched blood to follow individual patients over the course of chemotherapy. Results: We identified a cluster of KRT17 -high intermediary cancer cells that uniquely express high levels of CXCL8 and other cytokines. The proportion of KRT17 high /CXCL8 + cells in patient tumors correlated with intratumoral myeloid abundance, and, interestingly, high protumor peripheral blood granulocytes, implicating local and systemic roles. Patient-derived organoids maintained KRT17 high /CXCL8 + cells and induced myeloid cell migration in a CXCL8-dependent manner. In our longitudinal studies, plasma CXCL8 decreased following chemotherapy in responsive patients, while CXCL8 persistence portended worse prognosis. Conclusions: Through single-cell analysis of PDAC samples, we identified KRT17 high /CXCL8 + cancer cells as an intermediary subtype, marked by a unique cytokine profile and capable of influencing myeloid cells in the tumor microenvironment and systemically. The abundance of this cell population should be considered for patient stratification in precision immunotherapy. See related commentary by Faraoni and McAllister, p. 2297

Year:

2024

INTRODUCTION: There are no established guidelines on periprocedural and postprocedural pain management after endoscopic sleeve gastroplasty (ESG). This study aimed to determine the need for perioperative and postoperative opioid therapy in patients undergoing ESG. METHODS: This retrospective study comprised consecutive patients undergoing ESG. The primary outcome was the percentage of patients requiring postoperative outpatient opioid therapy. Secondary outcomes included frequency and dosage of perioperative pain medications and postoperative pain scores. RESULTS: Of the 67 patients included, 39 (58.2%) required opioids in the perioperative setting. The mean ± SD opioid dose was 12.3 ± 8.4 morphine milligram equivalents. Postoperatively, 17.9% of patients required home opioid prescriptions. More than a third of patients reported no pain. DISCUSSION: In patients undergoing ESG, postoperative opioid therapy should be individualized to attenuate opioid overprescription and the risk of opioid overuse.

Year:

2024

Collaborators (8)

Pierre A. Coulombe

G. Carl Huber Professor and Chair

University of Michigan

UNITED STATES
View details

Jorge Machicado

Assistant Professor

University of Michigan

UNITED STATES
View details

Marina Pasca Di Magliano

Associate Professor

University of Michigan

UNITED STATES
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Jiaqi Shi

Professor

University of Michigan

UNITED STATES
View details

Filip Bednar

University of Michigan

UNITED STATES
View details

Timothy Frankel

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Nina Steele

Assistant Professor

University of Cincinnati

UNITED STATES
View details